Last update 10 May 2026

Luye Jiaao (Shijiazhuang) Pharmaceutical Co., Ltd.

Subsidiary Company|2022|Hebei Sheng, China

Overview

Tags

Nervous System Diseases
Other Diseases
Endocrinology and Metabolic Disease
Small molecule drug

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Nervous System Diseases2
Endocrinology and Metabolic Disease2
Top 5 Drug TypeCount
Small molecule drug2
Top 5 TargetCount
D2 receptor(Dopamine D2 receptor)1
5-HT2A receptor x 5-HT2C receptor1

Related

2
Drugs associated with Luye Jiaao (Shijiazhuang) Pharmaceutical Co., Ltd.
Rotigotine
Target
D2 receptor
Mechanism
D2 receptor agonists
Active Org.
UCB Australia Pty Ltd. [+6]
Originator Org.
UCB SAUCB SA
Active Indication
Parkinson Disease [+2]
Inactive Indication
Arrhythmias, Cardiac [+5]
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
European Union [+3]
First Approval Date15 Feb 2006
LPM526000133
Target
5-HT2A receptor x 5-HT2C receptor
Mechanism
5-HT2A receptor inverse agonists [+1]
Active Org.
Luye Jiaao (Shijiazhuang) Pharmaceutical Co., Ltd. [+1]
Originator Org.
Luye Jiaao (Shijiazhuang) Pharmaceutical Co., Ltd.
Active Indication
Delusions [+4]
Inactive Indication-
Drug Highest PhasePhase 2
First Approval Ctry. / Loc.-
First Approval Date-
1
Clinical Trials associated with Luye Jiaao (Shijiazhuang) Pharmaceutical Co., Ltd.
CTR20254972
/ Not yet recruitingPhase 2
评价LPM526000133富马酸盐胶囊治疗阿尔茨海默病精神病性障碍（ADP）相关幻觉和妄想的初步疗效和安全性的随机、双盲、平行、安慰剂对照、IIa期临床研究
[Translation] A randomized, double-blind, parallel, placebo-controlled, phase IIa clinical study evaluating the preliminary efficacy and safety of LPM526000133 fumarate capsules in the treatment of hallucinations and delusions associated with Alzheimer's disease psychotic disorders (ADP).
100 Clinical Results associated with Luye Jiaao (Shijiazhuang) Pharmaceutical Co., Ltd.
Login to view more data
0 Patents (Medical) associated with Luye Jiaao (Shijiazhuang) Pharmaceutical Co., Ltd.
Login to view more data
100 Deals associated with Luye Jiaao (Shijiazhuang) Pharmaceutical Co., Ltd.
Login to view more data
100 Translational Medicine associated with Luye Jiaao (Shijiazhuang) Pharmaceutical Co., Ltd.
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 02 Jun 2026

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Phase 2
1
1
Approved
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
Rotigotine
 ( D2 receptor )		Parkinson Disease
More
Approved
LPM526000133
 ( 5-HT2A receptor x 5-HT2C receptor )		Hallucinations
More
Phase 2
Login to view more data

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free